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phenotype was compared to the previously reported canine 
dystrophinopathies. WGS was then used to detect a 7 base 
pair deletion in DMD exon 42 (c.6051-6057delTCT CAA T 
mRNA), predicting a frameshift in gene transcription and 
truncation of dystrophin protein translation. The deletion 
was confirmed with conventional PCR and Sanger sequenc-
ing. This mutation is in a secondary DMD gene hotspot 
area distinct from the one identified earlier at the 5′ donor 
splice site of intron 50 in the CKCS breed.
Introduction
Mutations in the Duchenne muscular dystrophy (DMD) 
gene result in decreased to absent dystrophin protein 
expression (Hoffman et  al. 1987). The extensive Leiden 
database of DMD gene mutations showed that 72% of 
mutations are intragenic deletions of one or more of the 79 
exons, with exons 45–53 being the most commonly affected 
region or hotspot (Aartsma-Rus et  al. 2006). Small dele-
tions, insertions, or point mutations account for a further 
20% of mutations (Aartsma-Rus et al. 2006). The remain-
ing approximately 7% of DMD gene mutations are caused 
by single or multi-exon duplications, with exons 2–20 
being the most commonly affected site (Aartsma-Rus et al. 
2006). Most mutations result in a frameshift, while oth-
ers affect RNA splicing or are nonsense mutations. Becker 
muscular dystrophy, a less severe dystrophinopathy, is char-
acterized by in-frame DMD gene mutations (Aartsma-Rus 
et al. 2006).
Multiplex ligation-dependent probe amplification 
(MLPA), a variation of multiplex polymerase chain reaction 
(PCR) is able to identify deletions and duplications involv-
ing one or more exons and is the most widely used molecu-
lar technique for diagnosis of DMD (Grimm et  al. 2012). 
Abstract Dystrophin is a key cytoskeletal protein coded 
by the Duchenne muscular dystrophy (DMD) gene located 
on the X-chromosome. Truncating mutations in the DMD 
gene cause loss of dystrophin and the classical DMD clini-
cal syndrome. Spontaneous DMD gene mutations and 
associated phenotypes occur in several other species. The 
mdx mouse model and the golden retriever muscular dys-
trophy (GRMD) canine model have been used extensively 
to study DMD disease pathogenesis and show efficacy 
and side effects of putative treatments. Certain DMD gene 
mutations in high-risk, the so-called hot spot areas can be 
particularly helpful in modeling molecular therapies. Iden-
tification of specific mutations has been greatly enhanced 
by new genomic methods. Whole genome, next generation 
sequencing (WGS) has been recently used to define DMD 
patient mutations, but has not been used in dystrophic 
dogs. A dystrophin-deficient Cavalier King Charles Spaniel 
(CKCS) dog was evaluated at the functional, histopatholog-
ical, biochemical, and molecular level. The affected dog’s 
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When combined with Sanger sequencing of genomic DNA 
(gDNA) or complementary DNA (cDNA) obtained from 
retro-transcription of DMD messenger RNA, these tech-
niques have a 97.3% sensitivity in detecting DMD gene muta-
tions (Grimm et al. 2012). However, sequencing of the entire 
12 kb DMD coding sequence is time consuming. Next gener-
ation sequencing (NGS) of either the whole genome (WGS) 
or targeted enrichment of the DMD gene provides a sensitive 
and specific molecular technique for DMD diagnosis (Wang 
et al. 2014; Roucher-Boulez et al. 2015; Okubo et al. 2016). 
Although the costs are still too high for NGS to be routinely 
implemented in the dystrophinopathy diagnostic workflow, 
NGS techniques are becoming more accessible and may soon 
represent a feasible alternative to the conventional approach 
for DMD patients and animal models.
Pre-clinical therapeutic development with animal systems 
is necessary to develop treatments for DMD boys. The preva-
lence of dystrophin deficiency worldwide for dogs and other 
non-human species is not known but appears rare based on 
the small number of reports in the literature. Mammalian 
models with confirmed DMD gene mutations that are used for 
pre-clinical research include the X-linked muscular dystrophy 
mouse (mdx) (Bulfield et al. 1984), several canine dystrophi-
nopathies (reviewed in Brinkmeyer-Langford and Kornegay 
2013 and summarized in Supplemental Table 1), most nota-
bly the golden retriever muscular dystrophy (GRMD) dog 
(Kornegay et al. 1988); the rat (Larcher et al. 2014); and the 
pig (Klymiuk et al. 2013). The mdx mouse and GRMD dog 
are most commonly used for pre-clinical testing of pathoge-
netic mechanisms and therapeutic development (Kornegay 
et  al. 2014). The clinical syndromes among affected canine 
breeds are fairly consistent, with generalized muscle weak-
ness, abnormal gait, and dysphagia typically being evident by 
3 months and progressing.
Mutations in DMD gene hotspot areas are particularly 
valuable in modeling molecular therapies. A recent report 
detailed a donor splice site mutation in intron 50 of the 
DMD gene in a group of Cavalier King Charles Spaniel 
(CKCS) dogs (Walmsley et  al. 2010), providing a signifi-
cant model to test exon skipping treatment strategies. In 
the CKCS dog studied here, clinical signs similar to other 
reported canine dystrophinopathies were evident at an early 
age and progressed. We used WGS in this dog to identify 
a 7 base pair (bp) deletion in exon 42, a secondary DMD 
gene hot spot area.
Materials and methods
Animal Use
The dog was used and cared according to principles out-
lined in the National Research Council’s Guide for the Care 
and Use of Laboratory Animals. The dog was first main-
tained at the University of North Carolina and then at Texas 
A&M University.
Microscopy
Methods for light and immunofluorescence microscopy 
have been described previously (Nghiem et al. 2013). Anti-
dystrophin antibodies from Novacastra (Buffalo Grove, 
IL) were against the rod and C-terminal domains (DYS1 
and DYS2) (1:100 dilution, antibodies combined into one 
experiment). Secondary antibody was goat anti-mouse 
Alexa Fluor IgG (1:500).
Western blot
7.5% of SDS–PAGE gels were made with BioRad (Hercu-
les, CA) TGX Stain-Free FastCast Acrylamide Starter Kit. 
Muscle tissue was ground with a homogenizer at 4 °C in 
RIPA buffer plus Halt Protease and Phosphatase Single-
Use Inhibitor Cocktail (Thermo Scientific; Waltham, MA). 
Total protein quantification was completed with BioRad’s 
RC DC Protein Assay. 50  µg of protein was loaded in a 
gel and electrophoresed for 1  h at 100  V. Proteins were 
transferred to a PVDF membrane for 1 h at 100 V. Mem-
branes were blocked in 5% bovine serum albumin (BSA) 
in TBS-T for 4 h. DYS1 and DYS2 were incubated with the 
PVDF membrane at 1:1,000 dilution in 5% BSA overnight 
at 4 °C. Sigma–Aldrich’s (St. Louis, MO) desmin antibody 
(D1033) was used as a loading control (1:1,000). Second-
ary goat anti-mouse IgG horseradish peroxidase antibody 
was obtained from Santa Cruz Biotechnology (Dallas, 
TX) and diluted to 1:5,000 in 5% BSA. Membranes were 
incubated in SuperSignal West Pico Chemiluminescent 
Substrate (Thermo Scientific) and exposed to radiographic 
film. Thermo Scientific Restore Western Blot Stripping 
Buffer was used to strip the blots.
PCR and sanger sequencing
To test for presence of the previously reported CKCS intron 
50 donor splice site mutation, we used primers developed 
in the earlier study (Walmsley et al. 2010). Total RNA was 
isolated from myoblasts extracted from the vastus lateralis 
(VL) muscle, as detailed previously (Nghiem et al. 2013). 
Genomic DNA was extracted from muscle tissue with 
Qiagen DNA Blood and Tissue Kit. Reverse transcriptase 
(RT)-PCR of total RNA was performed to make cDNA 
using the Applied Biosystems High Capacity cDNA kit 
(Foster City, CA), also described previously (Walmsley 
et al. 2010; Nghiem et al. 2013). PCR was performed with 
AccuPrime Supermix (Thermo Scientific) on a Thermocy-
cler, under the following conditions: 94 °C for 5 min; 94 °C 
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for 30 s, 58 °C for 30 s, 68 °C for 60 s (cycle repeated 35 
times); and 68 °C for 5 min. The PCR product was submit-
ted for Sanger sequencing and restriction fragment length 
polymorphism (RFLP) mutational analysis, as previously 
reported (Walmsley et al. 2010). A separate primer design 
for exons 45–53 can be found in supplemental methods 
(Supplemental Table 2). PCR was performed with identical 
conditions, as detailed above.
Nested PCR of gDNA was performed with primers 
flanking the targeted site at DMD exon 42. Outside sense 
and anti-sense primers were as follows: 5′-GTG GTT TAG 
GAA TTC CAC ATG TAC G-3′ and 5′-TGT CTA TAC CAG 
CAC ACT GTCC-3′, respectively. Inside sense and anti-
sense primers were as follows: 5′-CTA AGT CAA TCA TTG 
TAC TGCG-3′ and 5′-CGA TGA CTG AAG ACA TGC CTT 
TGG -3′, respectively. Reaction products were subjected to 
gel electrophoresis for quality control. Target bands were 
cut from the agarose gel and the DNA was extracted and 
processed. Transformation of the PCR product and cloning 
into the pCR 2.1 Vector was completed using the Invitro-
gen TA Cloning Kit, as recommended by the manufacturer. 
PCR products were submitted to the Texas A&M Gene 
Technology Lab for Sanger sequencing. Sequence chroma-
tograms were viewed with Sequencher (Gene Codes Cor-
poration; Ann Harbor, MI).
Whole genome sequencing
Genomic DNA was extracted from muscle using the Qia-
gen DNA Blood and Tissue Kit (Hilden, Germany). 2 µg 
of gDNA was prepared and sent to Macrogen (Rockville, 
MD), where it was clustered and sequenced on the Illumina 
HiSeq X Ten (San Diego, CA). Briefly, the gDNA was fur-
ther prepped according to the Illumina TruSeq DNA PCR-
free library preparation guide. DNA was fragmented and a 
final library of 300–400 base pair (bp) average insert size 
was created. Using an End Repair Mix, the double-stranded 
DNA 3′ or 5′ overhang fragments were converted into blunt 
ends, while the 3′–5′ exonuclease removed the 3′ over-
hangs and the polymerase filled the 5′ overhangs. After end 
repair, the appropriate library size was selected using Sam-
ple Purification Beads. 3′ end adenylation was performed 
by adding a single ‘A’ nucleotide to the blunted fragments 
along with a corresponding ‘T’ nucleotide to provide com-
plementary overhang for adapter ligation to the fragment. 
Multiple indexing adapters were ligated to DNA fragment 
ends and prepared for flow cell hybridization. Library vali-
dation, including a quality control analysis of the sample 
library and quantification of DNA library templates, was 
performed by Macrogen. The flow cell containing unique 
clusters was loaded into the HiSeq X Ten for automated 
cycles of sequencing by synthesis (extension and imaging). 
WGS data were aligned with Isaac aligner (Raczy et  al. 
2013). Isaac Variant Caller was used to identify and geno-
type single-nucleotide polymorphisms (SNPs) and small 
insertions/deletions (indels). A variant call format file was 
produced with the probability of consensus difference from 
genotype and probability of the called genotype. Mapping 
quality was performed by Phred-scaled probability of all 
samples and reported in −log. National Center for Biotech-
nology Information’s (NCBI) Genome Workbench software 
(Bethesda, MD) was used to evaluate mutations, SNPs, and 
indels within the DMD gene (compared to the CanFam3.1 




Clinical syndromes of dogs with confirmed dystrophin 
deficiency reported in the literature are summarized in Sup-
plemental Table 2. A 6-month-old, intact male CKCS dog 
(named Buckley) was presented to the University of Geor-
gia Small Animal Teaching Hospital for a 3 months history 
of dysphagia, ptyalism, nasal congestion, non-progressive 
coughing, lethargy, and decreased activity compared to 
other household dogs. The dog was obtained from a CKCS 
dog breeder at 3  months of age and noted to be smaller 
and have a weak bark compared to its littermates. It was 
also unable to properly masticate and swallow dry kibble. 
After eating, the dog exhibited cough and nasal congestion. 
Examination revealed generalized skeletal muscle atrophy, 
macroglossia, ptyalism, nasal discharge, and moderate 
bilateral carpal hyperextension (Fig. 1). It protracted both 
pelvic limbs simultaneously during trotting (indicative of a 
‘bunny-hopping’ gait), fatigued and subsequently collapsed 
after trotting for 1–2  min. No other abnormalities were 
detected on physical examination.
Biochemical analysis
A complete blood count revealed leukocytosis (white blood 
cell count of 24,600/µl; normal value [n.v.] 5.5–13,900/
µl), with increased numbers of mature neutrophils (16,482/
µl; n.v. 2.9–12,000/µl), lymphocytes (5,900/µl; n.v. 0.4-
2,900/µl), and eosinophils (1,400/µl; n.v. 0–1,300/µl). A 
biochemistry panel revealed increased serum activity of 
creatine kinase (CK; 29,170 U/L; n.v. 63–350 U/L), AST 
(472 U/L (no reference range available), and ALT 705 U/L; 
n.v. 12–108  U/L). Concentrations of BUN (8  mg/dl; n.v. 
10–30  mg/dl) and creatinine (0.4  mg/dl; n.v. 0.5–1.5  mg/
dl) were decreased. Urinalysis was unremarkable. Pre and 
post-prandial bile acid concentrations, measured to rule out 
hepatobiliary disease, were also unremarkable.
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Diagnostic imaging
Thoracic radiographs suggested left ventricular enlarge-
ment with no evidence of atrial enlargement. A small 
amount of fluid was seen in the caudal thoracic esopha-
gus. The liver appeared smaller than normal. An echocar-
diogram study revealed mild systolic and diastolic dys-
function, including prolonged isovolemic contraction and 
relaxation times. Myocardial wall thickness, contractility, 
velocity of contractility, and ejection fraction were within 
normal limits. A cervical ultrasonogram did not reveal 
abnormalities. The lateral survey projection of a pharyngo-
esophogram revealed focal accumulation of gas bubbles 
in the mid cervical esophagus. Oral pharyngeal bolus for-
mation and esophageal progressive motility were within 
normal limits on fluoroscopy, but small amounts of liquid 
barium food mixture consistently accumulated in the cervi-
cal esophagus. There was no evidence of achalasia or an 
esophageal stricture.
Due to the dog’s condition, an inherited muscle disease 
was suspected, and it was donated for further study. The 
dog was subsequently transferred to the University of North 
Carolina-Chapel Hill and then to Texas A&M University. 
Gradual disease progression was observed over the next 5 
years, at which time the dog died due to complications dur-
ing anesthesia.
Necropsy and histopathological analysis
The dog had variable muscle atrophy and hypertrophy on 
gross necropsy. Histopathological analysis focused on the 
cranial sartorius (CS) and vastus lateralis (VL) head of 
the quadriceps, as these muscles are differentially affected 
in golden retriever muscular dystrophy (GRMD) dogs 
(Nghiem et  al. 2013). Similar to our previous studies, the 
VL muscle showed classic dystrophic changes, including 
variation in myofiber size, myofiber necrosis, inflammation, 
and increased perimysial connective tissue (Fig.  2b). The 
CS muscle showed similar dystrophic changes, but consist-
ent with our findings in GRMD (Nghiem et al. 2013), the 
myofibers were hypertrophied compared to normal and the 
dystrophic VL muscle (Fig. 2a-c).
Immunofluorescence microscopy and western blotting
Together with the dog’s male gender, the elevated serum 
CK activity and dystrophic skeletal muscle changes were 
highly suggestive of a dystrophinopathy. Dystrophin pro-
tein immunostaining was absent in the CS and VL muscles, 
except for occasional revertant fibers, particularly in the 
CS muscle (Fig.  2d, e). Uniform membranous dystrophin 
staining was seen in a normal 6-month-old dog muscle tis-
sue used as control (3F). Dystrophin was detected in con-
trol muscle tissue on western blot, but not in the affected 
CKCS muscles (Fig. 2g). Desmin, an intermediate filament 
in skeletal muscle tissue, was used as a protein loading con-
trol. Interestingly, desmin appeared to be increased in the 
hypertrophied CS muscle compared to the dystrophic VL 
and also normal muscle (Fig. 3g).
Utrophin is homologous with dystrophin and upregu-
lated in dystrophin deficiency, potentially serving as a dys-
trophin surrogate (Matsumura et  al. 1992; Tinsley et  al. 
1998; Cerletti et al. 2003; Nghiem et al. 2013). We probed 
CS and VL muscles of the affected dog and found a sub-
tle increase in utrophin at the myofiber membrane, con-
sistent with our previous studies in GRMD dogs (Fig. 2h) 
(Nghiem et al. 2013). Utrophin expression in control canine 
muscle, as expected, was localized to neuromuscular junc-
tions and absent in the myofiber membranes (Fig. 2i).
Molecular analysis of gDNA
A donor splice site mutation (G–T nucleotide mutation) in 
intron 50 was previously characterized in a group of CKCS 
dogs (Walmsley et al. 2010). As such, we sought to deter-
mine if the CKCS dog in this study had the same mutation. 
However, the previously characterized splice site muta-
tion in intron 50 was not detected by Sanger sequencing 
and RFLP (results not shown). To further investigate the 
causative mutation, we developed primers for the known 
mutational hotspot at exons 45–53, and performed PCR 
on extracted gDNA. Agarose gel electrophoretic analysis 
did not detect a banding pattern suggestive of deletions or 
duplications compared to a normal dog sample (results not 
shown).
To continue characterization of the DMD gene in this 
CKCS dog, we performed WGS using the Illumina HiSeq 
X Ten. The affected sample was compared and refer-
enced to the 2,410,976,875 base-length CanFam3.1 whole 
Fig. 1  Cavalier King Charles Spaniel dog with dystrophin defi-
cient muscular dystrophy at 6-month-old. Note the generalized skel-
etal muscle atrophy of the temporal region, limbs and thoracolumbar 
spine
110 P. P. Nghiem et al.
1 3
genome shotgun sequence (Hoeppner et al. 2014). Mapped 
sites greater than 1X coverage included 2,374,293,654 
bases (98.48% of reference genome) with a total read count 
of 821,908,096. Mapped reads and bases of 696,176,213 
(84.7%) and 99,774,575,483, respectively, were refer-
enced back to CanFam3.1. The mean alignment depth was 
41.38. Isaac Variant Caller detected 265,324, 248,521, and 
1,518,125 SNPs, insertions and deletions, respectively, 
which were classified by chromosomes or scaffolds. Dupli-
cations were not called.
Evaluation of the entire DMD gene (X chromosome, 
NC_006621.3; 26,290,903..28,444,730) in the CKCS 
dog revealed 1,007 SNPs and indels (Supplemental 
Table 3). A 7-bp deletion was detected in exon 42 (posi-
tions 27,442,987..27,442,993) (c.6051_6057delTCT CAA 
T mRNA mutation) (Fig.  3). The deletion predicted a 
frameshift mutation at amino acid 2017 (leucine) with a 
stop codon introduced 18 amino acids downstream and 
premature stoppage of translation (p.Leu2017Leufs*18). 
PCR of the affected region around the DMD exon 42 
deletion, followed by Sanger sequencing, were performed 
to validate the WGS reads. Normal and dystrophin defi-
cient GRMD (splice site mutation in intron 6 of DMD 
gene) (Kornegay et al. 1988; Sharp et al. 1992) samples 
showed the correct 7-bp in exon 42 (Fig. 3; Supplemental 
Table 4).
Fig. 2  Histopathological and immunofluorescence analyses of dys-
trophic muscle in the CKCS dog. a Cranial sartorius (CS) muscle of 
the affected CKCS dog showed myofiber size variation with hyper-
trophy (white dotted outline), myofibers with central nuclei indicating 
regeneration, increased perimyseal connective tissue, inflammation, 
and myofiber necrosis (white arrow). b Vastus lateralis (VL) muscle 
of the CKCS dog showed myofiber size variation (dotted line) as a 
result of degeneration and regeneration, increased perimysial connec-
tive tissue, immune cell infiltration, and hypercontracted (hyaline) 
fibers (white arrow). C: Normal dog muscle at 6 months of age. Note 
the uniform size of myofibers, myonuclei at the periphery, and lack 
of both immune cell infiltration, and increased perimysial connec-
tive tissue. d, e Dystrophin (DYS1 and DYS2) protein immunostain-
ing of the affected CKCS dog showed a small amount of dystrophin 
revertant fibers, more so in the CS (d) compared to the VL (e) mus-
cle (white arrows). f Normal dog muscle at 6 months showed mem-
branous staining of dystrophin protein. g Western blot: Dystrophin 
(DYS1 and DYS2) was detected in normal muscle, but not in the CS 
or VL of the affected CKCS. Desmin was used as a loading control. 
Note that desmin, an intermediate filament that localizes to the sar-
colemma, was increased in the hypertrophied, dystrophin-deficient 
CS muscle. h Utrophin protein immunostaining of the CKCS dog 
showed subtle membranous staining in the CS (not shown) and VL 
(h) muscles with no difference in expression between the muscles. i 
Utrophin protein immunostaining in normal dog muscle was confined 
to regions consistent with neuromuscular junctions. Marker = 50 µm; 
×100 magnification (×10 ocular, ×10 objective)
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Discussion
This report details a dystrophin-deficient CKCS with pro-
gressive clinical signs until 6 months of age at which time 
the dog clinically stabilized. This phenotype is in keep-
ing with dystrophin-deficient GRMD dogs perpetuated for 
research purposes (Valentine et  al. 1988). We used WGS 
to identify a 7-bp deletion in exon 42 of the DMD gene, 
predicting a frameshift mutation and premature halting of 
translation. This mutation is in a secondary hotspot area 
distinct from a previously identified splice site mutation 
in CKCS dogs (Walmsley et  al. 2010), thereby providing 
a potential valuable canine model. Moreover, our study 
establishes WGS as a viable option compared to conven-
tional PCR and Sanger Sequencing to characterize DMD 
gene mutations in dogs.
The studied CKCS dog presented to the referring vet-
erinarian at 6  months of age with typical historical and 
clinical signs of muscular dystrophy, including small stat-
ure, exercise intolerance, dysphagia, coughing, and a weak 
bark. Other reported historical and clinical signs in various 
DMD dog breeds include generalized weakness and other 
gait abnormalities, muscular atrophy, paradoxical muscle 
hypertrophy, ptyalism, collapse, with dogs surviving from 3 
to 152 months of age (Kornegay et al. 1988; Valentine et al. 
1988; Winnand et al. 1994; Schatzberg et al. 1999; Wetter-
man et al. 2000; Shelton et al. 2001; Bergman et al. 2002; 
Jones et al. 2004; Wieczorek et al. 2006; Baltzer et al. 2007; 
Walmsley et al. 2010; Olby et al. 2011; Smith et al. 2011; 
Beltran et  al. 2015; Jenkins et  al. 2015). The dog in this 
report had a clinical course typical of that seen with other 
canine dystrophinopathies, succumbing at 60 months. On a 
related note, we are currently conducting molecular stud-
ies in a cohort of 52 mildly affected, dystrophin-deficient 
GRMD dogs that have lived greater than 36 months of age 
(median = 65  months, 95% CI 55–76  months) (Nghiem, 
Kornegay, Bello, unpublished data).
Upon finding that the studied dog did not have the CKCS 
intron 50 mutation, we expanded our analysis to include 
exons 45 through 53, the known mutation hotspot in DMD 
patients, but conventional PCR was uninformative. Whole 
genome sequencing then revealed a 7-bp deletion of exon 
42 that was confirmed with PCR and Sanger sequencing. 
The nonsense mutation predicted a frameshift mutation and 
a termination of translation. By eliminating steps of selec-
tive capture and amplification of specific genomic regions, 
Fig. 3  Whole genome sequenc-
ing revealed a 7-bp deletion 
in exon 42 of the DMD gene. 
a WGS reads (bottom part of 
image) show the 7-bp dele-
tion (AGC ATT A) in exon 42 
(bracket). b Chromatograms of 
PCR product Sanger sequencing 
confirmed the 7-bp deletion in 
exon 42 of the affected CKCS 
dog. Normal and the dystro-
phin-deficient GRMD dog (with 
splice site mutation in intron 6) 
revealed the 7-bps were present 
in exon 42 of the DMD gene 
(black box outline)
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WGS ensures homogeneous read depth in all genomics 
regions, increasing sensitivity, even for mutations in coding 
regions. Moreover, these techniques have become increas-
ingly cost effective, making characterization of novel DMD 
gene mutations in dogs and assessment of pre-clinical 
molecular trials more practical. While the ~$1,000–2,500 
per sample cost of WGS is currently more expensive than 
conventional PCR and Sanger Sequencing, the time for 
data generation/interpretation is much improved (~4–8 
weeks for data generation; ~4 weeks for interpretation).
A significantly improved canine reference sequence, 
CanFam3.1, now covers 99.8% of the euchromatic canine 
genome, making WGS data much easier to analyze, espe-
cially in GC rich regions such as promoters and first exons 
(Hoeppner et al. 2014). On the other hand, because WGS 
can detect millions of changes in the genome, determin-
ing the clinical significance of the many polymorphisms 
can be challenging. In the studied CKCS dog, we detected 
over 2 million genomic variants. Further analyses of these 
other genomic variants are currently underway. We used 
NCBI’s Genome Browser to analyze the WGS data; other 
softwares are also available. Finally, certain inbred dogs 
may show genetic divergence due to outbreeding (to reduce 
mortality related deaths due to high inbreeding) (Korne-
gay et al. 2011). This genetic divergence may pose issues 
for researchers attempting to evaluate genetic causes of 
disease.
Although not considered part of the main exon 45–53 
DMD gene hot spot, a recent report identified mutations in 
exon 42 in 2% of the DMD patient cohort (Barzegar et al. 
2015). To our knowledge, this is the first canine dystro-
phinopathy in which an exon 42 mutation was identified. 
In theory, if the mutated DMD gene transcript was not 
subjected to nonsense-mediated decay, the studied CKCS 
dog could have a less severe phenotype. Notably, dystro-
phin transcript apparently avoids nonsense decay and per-
sists in GRMD dogs (Cotten et al. 2013). Immunofluores-
cence microscopy revealed a small amount of dystrophin 
revertant fibers, particularly in the relatively preserved 
and hypertrophied CS muscle. In contrast, dystrophin was 
completely absent on immunostaining in the CKCS dogs 
reported in separate studies by Walmsley et al. and Schatz-
berg (Walmsley et al. 2010; Schatzberg and Shelton 2004). 
Dystrophin expression in the CS muscle could occur due 
to either persistence of protein containing exons 1 through 
41 (escaping nonsense-mediated decay) or from alterna-
tively spliced dystrophin mRNA products (Cotten et  al. 
2013; Schatzberg et  al. 1998). This CKCS model could 
also be valuable in studying molecular therapies such as 
exon skipping (Aartsma-Rus 2012) or gene editing, target-
ing exon 42. Similar to many other exons encoding the rod 
domain of dystrophin, where small pathogenetic mutations 
often localize, exon 42 is an in-frame exon consisting of a 
multiple-of-three number of nucleotides (195). Its splicing 
consensus sequences may be masked by an oligonucleotide 
at the transcript level (exon skipping), or disabled by gene 
editing at the genomic level (exon snipping, Kemaladewi 
and Cohn 2016), to inhibit inclusion of this exon in the 
mature transcript, and restore the open reading frame of 
dystrophin. We are evaluating options to perpetuate this 
canine model.
Because of its similar structure and function, utrophin 
could act as a dystrophin surrogate to stabilize dystrophic 
myofiber membranes (Tinsley et  al. 1998; Cerletti et  al. 
2003; Nghiem et  al. 2013). Consistent with our previous 
studies in GRMD dogs (Nghiem et  al. 2013), the CKCS 
dog of this report had a subtle increase in utrophin at the 
myofiber membrane in both the hypertrophied CS and dys-
trophic VL muscles. Associated stabilization of the dys-
trophic membrane could have contributed to this dog liv-
ing to middle age. However, importantly, mildly affected 
GRMD dogs used for breeding in our colony routinely live 
well into adulthood, in keeping with disease amelioration 
from gene modifiers or other genetic mechanisms. Based 
on data reported here and in GRMD dogs (Nghiem and 
Kornegay, unpublished), desmin may contribute to another 
compensatory pathway in the spared/hypertrophied CS 
muscle.
In conclusion, the studied CKCS dog had typical, pro-
gressive clinical signs of dystrophin deficiency. WGS is a 
viable diagnostic option to characterize DMD gene muta-
tions in dystrophic canines. The 7-bp deletion in exon 42 
is analogous with those seen in DMD patients. If perpetu-
ated, this model could have value in studying mechanisms 
that ameliorate the dystrophic phenotype, to include genetic 
therapies such as exon skipping and gene editing.
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